Ije Nwokori Acquires 118,516 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Ije Nwokori purchased 118,516 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was acquired at an average price of GBX 72 per share, with a total value of £85,331.52.

Ije Nwokori also recently made the following trade(s):

• On Thursday, June 11th, Ije Nwokori purchased 202 shares of Dr. Martens stock. The stock was acquired at an average cost of GBX 74 per share, with a total value of £149.48.
• On Friday, June 12th, Ije Nwokori purchased 112,500 shares of Dr. Martens stock. The shares were acquired at an average price of GBX 76 per share, for a total transaction of £85,500.
• On Wednesday, May 13th, Ije Nwokori acquired 233 shares of Dr. Martens stock. The shares were bought at an average price of GBX 64 per share, for a total transaction of £149.12.
• On Wednesday, April 15th, Ije Nwokori sold 204,051 shares of Dr. Martens stock. The shares were sold at an average price of GBX 66, for a total transaction of £134,673.66.
• On Tuesday, April 14th, Ije Nwokori acquired 232 shares of Dr. Martens stock. The stock was bought at an average cost of GBX 65 per share, with a total value of £150.80.

Dr. Martens Stock Performance

DOCS stock traded down GBX 0.90 during trading on Friday, reaching GBX 71.10. The company had a trading volume of 714,890 shares, compared to its average volume of 8,611,851. The firm has a 50-day simple moving average of GBX 68.37 and a 200-day simple moving average of GBX 69.35. The company has a market cap of £680.49 million, a price-to-earnings ratio of 29.62, a price-to-earnings-growth ratio of 6.40 and a beta of 0.25. The company has a debt-to-equity ratio of 108.27, a quick ratio of 1.13 and a current ratio of 2.61. Dr. Martens plc has a twelve month low of GBX 59.15 and a twelve month high of GBX 100.87.

Dr. Martens (LON:DOCS) last released its earnings results on Tuesday, May 19th. The company reported GBX 4.20 earnings per share for the quarter. The company had revenue of £764.90 million for the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. As a group, sell-side analysts expect that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Analyst Upgrades and Downgrades

DOCS has been the subject of a number of research analyst reports. Royal Bank Of Canada restated a “sector perform” rating and issued a GBX 100 target price on shares of Dr. Martens in a research note on Tuesday, June 2nd. Berenberg Bank cut their price objective on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of GBX 105.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.